Early human B cell response to Ebola virus in four U.S. survivors of infection by Williamson, Lauren E. et al.
 1 
Early human B cell response to Ebola virus in four U.S. survivors of infection  1 
 2 
Lauren Williamson
a
, Andrew I. Flyak
a,h
, Nurgun Kose
c
, Robin Bombardi
c
, Andre Branchizio
c
, Srikar 3 
Reddy
d
, Edgar Davidson
d
, Benjamin Doranz
d
, Marnie L. Fusco
e
, Erica Ollmann Saphire
e
, Peter J. 4 
Halfmann
f
, Yoshihiro Kawaoka
f
, Ashley E. Piper
g
, Pamela J. Glass
g
, James E. Crowe, Jr.
a,b,c#
 5 
 6 
Departments of Pathology, Microbiology, and Immunology
a
, Pediatrics
b
, and The Vanderbilt Vaccine 7 
Center
c
, Vanderbilt University Medical Center, Vanderbilt University, Nashville, TN 37232, USA; 8 
Integral Molecular, Philadelphia, PA, 19104, USA
d
; Departments of Immunology and Microbial 9 
Science, The Scripps Research Institute La Jolla, CA 92037, USA
e
; Influenza Research Institute, 10 
Department of Pathobiological Sciences, School of Veterinary Medicine, University of Wisconsin, 11 
Madison, WI, USA
f
; Virology Division, US Army Medical Research Institute of Infectious Diseases, 12 
MD 21702, USA
g
; Present address: Division of Biology and Biological Engineering, California 13 
Institute of Technology, Pasadena, CA 91106, USA
h 
14 
 15 
#Address correspondence to: james.crowe@vanderbilt.edu 16 
 17 
 18 
Running Title: Early human B cell response to Ebola virus disease 19 
 20 
Keywords: Ebola virus; Antibodies, Human; Antiviral; Filoviridae Infections; Protection; 21 
Hemorrhagic Fever, Ebola; Antibodies, Neutralizing. 22 
 23 
  24 
JVI Accepted Manuscript Posted Online 6 February 2019
J. Virol. doi:10.1128/JVI.01439-18
Copyright © 2019 American Society for Microbiology. All Rights Reserved.
 o
n
 February 6, 2019 by guest
http://jvi.asm.org/
D
ow
nloaded from
 
 2 
ABSTRACT 25 
 26 
The human B cell response to natural filovirus infections early after recovery is poorly understood. 27 
Previous serologic studies suggest that some Ebola virus survivors exhibit delayed antibody responses 28 
with low magnitude and quality. Here, we sought to study the population of individual memory B cells 29 
induced early in convalescence. We isolated monoclonal antibodies (mAbs) from memory B cells from 30 
four survivors treated for Ebola virus disease (EVD) one or three-months after discharge from hospital. 31 
At the early time points post-recovery, the frequency of Ebola-specific B cells was low and dominated 32 
by clones that were cross-reactive with both Ebola glycoprotein (GP) and with the secreted form 33 
(sGP). Of 25 mAbs isolated from four donors, only one exhibited neutralization activity. This 34 
neutralizing mAb, designated mAb EBOV237, recognizes an epitope in the glycan cap of the surface 35 
glycoprotein. In vivo murine lethal challenge studies showed that EBOV237 conferred protection when 36 
given prophylactically at a level similar to that of the ZMapp component mAb 13C6. The results 37 
suggest that the human B cell response to EVD one to three months post-discharge is characterized by 38 
a paucity of broad or potent neutralizing clones. However, the neutralizing epitope in the glycan cap 39 
recognized by EBOV237 may play a role in the early human antibody response to EVD and should be 40 
considered in rational design strategies for new Ebola virus vaccine candidates. 41 
 42 
IMPORTANCE 43 
 44 
The pathogenesis of Ebola virus disease (EVD) in humans is complex, and the mechanisms 45 
contributing to immunity are poorly understood. In particular, it appears that the quality and magnitude 46 
of the human B cell response early after recovery from EVD may be reduced compared to most viral 47 
infections. Here we isolated human monoclonal antibodies from B cells of four survivors of EVD at 48 
one or three months after hospital discharge. Ebola-specific memory B cells early in convalescence 49 
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 3 
were low in frequency, and the antibodies they encoded demonstrated poor neutralizing potencies. One 50 
neutralizing antibody that protected mice from lethal infection, EBOV237, was identified in the panel 51 
of 25 human antibodies isolated. Recognition of the glycan cap epitope recognized by EBOV237 52 
suggests this antigenic site should be considered in vaccine design and treatment strategies for EVD.  53 
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 4 
INTRODUCTION 54 
 55 
Ebola virus is a member of the Filoviridae family and causes intermittent outbreaks of severe human 56 
Ebola Virus Disease (EVD). Currently, there is an outbreak in the North Kivu province of the 57 
Democratic Republic of Congo (DRC), declared by the DRC Ministry of Health on August 1, 2018. As 58 
of August 15, 2018, there are confirmed 51 cases of Ebola, including 17 deaths (1). In 2014, a large 59 
outbreak occurred in West Africa, with a total of 28,616 cases of EVD and 11,310 deaths that were 60 
reported in Guinea, Liberia, and Sierra Leone, and an additional 36 cases and 15 deaths that occurred 61 
when the outbreak spread outside of these three countries (2).  Experimental vaccines, antibodies, 62 
small molecule, and RNA treatments for Ebola virus infection are in development, which are intended 63 
to prevent or treat infection using immunologic principles. Indeed, we and others have shown that at 64 
late time points after recovery, survivors possess memory B cells in circulation specifying broad and 65 
potent protective antibodies (3-8). Monoclonal antibodies (mAbs) isolated from human B cells of 66 
survivors can exert potent therapeutic effects in experimental infection models in nonhuman primates 67 
using cocktails of mAbs or even monotherapy (9-11). 68 
 69 
Ebola virus is an enveloped, non-segmented, negative-sense strand RNA virus. Together with the 70 
Marburg and Cuevaviruses, these members constitute the Filoviridae family. There are six species of 71 
Ebola virus: Zaire ebolavirus (EBOV), Bundibugyo ebolavirus (BDBV), Sudan ebolavirus (SUDV), 72 
Taï Forest ebolavirus (TAFV), Reston ebolavirus (RESV), and Bombali ebolavirus (BOMV). Of these 73 
species, EBOV, BDBV, and SUDV are the primary species associated with lethal disease in humans 74 
(3). The surface glycoprotein (GP) of Ebola virus is the major target of neutralizing antibodies. The 75 
envelope glycoprotein gene of Ebola virus encodes for two GPs through transcriptional editing. The 76 
major product of the gene is a 364-residue soluble, dimeric form of the GP (sGP). The precise role of 77 
sGP in Ebola virus infection is not clear. However, it is thought that sGP may serve as a decoy to 78 
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 5 
distract the immune response for virus evasion or contribute to pathogenesis (13). The minor product 79 
of the gene is a 676-residue viral surface  glycoprotein (GP) that is anchored to the viral envelope. The 80 
GP consists of two subunits, GP1 and GP2, these form a trimeric structure on the virus surface. The 81 
GP1 subunit contains the heavily glycosylated mucin-like domain and a glycan cap, which are cleaved 82 
proteolytically by cathepsins within the endosome during virus entry into the host cell (13,14). This 83 
exposes the receptor-binding site on the GP1 subunit that interacts with the endosomal receptor, 84 
domain C of the Niemann-Pick C1 protein (NPC1) (15). Upon receptor binding, the fusion loop of the 85 
GP2 subunit becomes exposed, enabling fusion of the virus with the endosomal membrane (13,14). 86 
The involvement of GP in virus attachment and entry into host cells, receptor binding within the 87 
endosome, and membrane fusion with the endosomal membrane, results in the GP being the major 88 
target of neutralizing mAbs (7). 89 
 90 
Cocktails of murine-human chimeric (ZMapp, ZMab, and MB-003) and human mAbs administered as 91 
a monotherapy have shown potent neutralizing and non-neutralizing activities for prevention and 92 
treatment of Ebola virus (EBOV) in experimental infection animal models, including ZMapp 93 
protection of nonhuman primates (9-11). The mAbs characterized target diverse antigenic sites on GP, 94 
including the glycan cap, GP1 receptor-binding site, GP1 head, GP1/GP2 interface, GP2 fusion loop, 95 
GP2 stalk, and HR2/MPER region (3-8, 15-21). Several mAbs that recognize antigenic sites present on 96 
the glycan cap and GP1 head are cross-reactive with sGP (3, 7, 13, 16, 21). The ZMapp cocktail (2G4, 97 
4G7, and 13C6) consists of three murine-human chimeric mAbs that recognize EBOV GP. 2G4 and 98 
4G7 recognize the base of the GP at the GP1/GP2 interface and exhibit potent neutralization activity in 99 
vitro (19-21). The other component of ZMapp is a weakly neutralizing mAb, 13C6, which recognizes 100 
the glycan cap and cross reacts with EBOV sGP. 101 
 102 
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 6 
The characterization of mAbs isolated at late time points after recovery has been described previously, 103 
however, the early human B cell response to EBOV is still poorly understood, especially at the clonal 104 
level. To investigate the early response to EBOV infection, we took advantage of an unprecedented 105 
opportunity to study the acute response to infection of four U.S. heath care workers, infected in West 106 
Africa, who had received intensive care treatment and monitoring at Emory University Hospital. The 107 
acute response to infection was characterized by an unusually long period of immune activation, as 108 
evidenced by the persistence of activated CD8 and CD4 T cells and plasmablasts even 1 month after 109 
the patients' discharge from the hospital and other persistent signs of immune activation (22). Studies 110 
also have revealed very prolonged maintenance of infectious virus in immune privileged sites 111 
including eye (23, 24) and semen (25), that can last over 2 years. Both polyclonal and monoclonal 112 
antibodies have been shown to exert potent antiviral effects against filovirus infection and disease in 113 
preclinical models. Indeed, we and others have shown that at late time points after recovery survivors 114 
possess memory B cells in circulation specifying broad and potent protective antibodies (3-8). 115 
However, the early human B cell response to EBOV is poorly defined. Here, we investigated the B cell 116 
response in survivors one and three-months post-discharge, at a time when immune activation persisted 117 
and virus may have persisted in immune privileged sites. The results show that soon after resolution of 118 
viremia, the memory B cell response in blood is characterized by a low frequency of EBOV-specific B 119 
cells, with the antibodies encoded by those cells displaying low neutralizing activity. 120 
  121 
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 7 
RESULTS 122 
 123 
Isolation of human GP-reactive mAbs from Ebola survivors. PBMCs were isolated from patients 124 
that survived EVD (designated subjects EVD2, EVD5, EVD9, or EVD15), one or three-months after 125 
their discharge from Emory University Hospital. PBMCs were transformed with EBV and after 126 
expansion cell supernatants were screened to determine the relative magnitude of B cell responses to 127 
soluble forms of the Ebola virus (EBOV), Bundibugyo virus (BDBV), Sudan virus (SUDV), and 128 
Marburg virus (MARV) glycoprotein (GP) ectodomains. From the corresponding ELISA data, Circos 129 
plots were generated to illustrate the cross-reactivity of the B cell responses for each donor to the 130 
varying glycoproteins  (Figure 1A). Relative height of each bar indicates the optical density (O.D.) 131 
values at 405 nm as determined by ELISA. Subjects EVD2 and EVD5 had a greater and broader B cell 132 
response to these GPs one-month after hospital discharge in comparison to donors EVD9 and EVD15. 133 
However, an increase in B cell response to these GPs was observed for donor EVD15 at three-months 134 
after hospital discharge compared to one-month. Reactivity of EBOV GP and sGP-specific B cell lines 135 
were primarily EBOV GP/sGP cross-reactive (Figure 1B) for all donors at both time points, except for 136 
EVD15 at one-month time point (EVD15_1).  Additionally, a majority of the B cell reactivity was 137 
towards EBOV GP and sGP. There was an increase in cross-reactivity to BDBV GP of donor samples 138 
at three-months compared to one-month post discharge, indicating that development of these 139 
antibodies occurred over the period of recovery. A minor percentage of reactive B cells were cross-140 
reactive to EBOV, BDBV, and SUDV GP and again increased at three-months compared to one-month 141 
post-discharge time points. 142 
 143 
We isolated human mAbs specific to EBOV, BDBV, and SUDV glycoproteins (GP) or EBOV soluble 144 
glycoprotein (sGP) from transformed B cells. A panel of 25 human mAbs was isolated. The half-145 
maximal effective concentration of binding (EC50) values for the EBOV GP-reactive human mAbs as 146 
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 8 
determined via ELISA are indicated in Figure 2A. The mAbs exhibited values for EC50 in diverse 147 
ranges including 0 – 100 ng/mL, 100 – 1,000 ng/mL, 1,000 – 10,000 ng/mL, or greater than 10,000 148 
ng/mL, as indicated in the heat map by dark red, orange, or yellow color, or a greater-than sign (>), 149 
respectively. The EBOV GP-reactive human mAbs are separated into four groups, with two subgroups 150 
(A and B) for groups 1 and 2 designated based on pattern of reactivity to the various GPs. The A 151 
subgroup indicates mAbs that bound GP and EBOV sGP, suggesting the GP1 glycan cap as the GP 152 
binding site for these mAbs, whereas mAbs from the B subgroup bound GP only. Increasing in cross-153 
reactivity, group 1 bound EBOV, group 2 bound EBOV and BDBV or SUDV, and group 3 bound 154 
EBOV, BDBV, and SUDV. Group “sGP” mAbs bound to EBOV sGP only. None of these mAbs 155 
bound to MARV GP. Isolation of mAbs, primarily from donors EVD2 and EVD5 one and three-156 
months post-discharge, reflects the intensity and broad B cell response measured initially with EBV-157 
transformed B cell line supernatants, as indicated by the Circos plots (Figure 1A). 158 
 159 
EBOV237, a neutralizing mAb. To determine the antiviral activity of the EBOV GP reactive human 160 
mAbs, neutralization assays were performed against Ebola Zaire (EBOV/Kik-9510621, CDC#807224). 161 
Plaque reduction neutralization test (PRNT) assays were performed to determine the endpoint titer for 162 
50% (PRNT50) or 80% (PRNT80) reduction in plaques compared to an virus only control. From the 163 
panel of 25 human EBOV mAbs, one mAb (designated EBOV237) was neutralizing with a PRNT50 of 164 
0.78 µg/mL and a PRNT80 of 1.56 µg/mL (Figure 2C). 165 
 166 
A representative curve for binding of EBOV237 to full-length EBOV, BDBV, SUDV, MARV GPs, or 167 
EBOV sGP is shown in Figure 2B. EBOV237 bound to EBOV GP, BDBV GP or EBOV sGP with 168 
EC50 values of 25, 3,367, or 9 ng/mL, respectively. EBOV237 did not bind SUDV and MARV GPs. 169 
Thus, EBOV237 primarily binds to EBOV GP, EBOV sGP, and BDBV GP, albeit with lower affinity. 170 
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 9 
Stronger binding of EBOV237 to EBOV GP in comparison to the other EBOV human mAbs 171 
correlated with its neutralization activity towards EBOV. 172 
 173 
Epitope mapping of EBOV237 to the glycan cap region of EBOV GP1. To determine the epitopes 174 
recognized by the panel of EBOV human mAbs, competition-binding assays were performed with 175 
mAbs that bound to EBOV GP or sGP as determined by a > 0.19 nm shift in the interfence pattern of 176 
light through bio-layer interferometry. Four epitope groups were identified on EBOV GP from the 177 
panel of EBOV human mAbs. Recombinant forms of two mAbs that are components of the ZMapp 178 
therapeutic cocktail (2G4 and 13C6) were used as controls for binding to EBOV GP. The epitopes for 179 
2G4 and 13C6 are known, as they bind to the base of the GP or to the GP1 glycan cap, respectively 180 
(20, 21). None of the mAbs tested competed with 2G4, indicating that these mAbs do not bind to the 181 
base of EBOV GP. EBOV237 did not compete for binding with either 2G4 or 13C6 (Figure 3A), 182 
indicating that EBOV237 binds to a distinct site on EBOV GP. EBOV237 competed for binding with 183 
EBOV173 and EBOV236, suggesting that these human EBOV mAbs bind similar sites on EBOV GP. 184 
Several unidirectional pairs were identified as well, such as EBOV173 and 13C6. This may be due to 185 
difference in angle of binding of the first mAb relative to the second mAb. This could allow for 186 
binding of the mAb in one direction but not in the other. Additionally, the relative kinetics of binding 187 
for the first mAb may also account for the unidirectional competition of mAb binding. EBOV237 and 188 
a previously isolated neutralizing BDBV mAb, BDBV43 (3), were competed with the human EBOV 189 
mAbs on EBOV sGP (Figure 3B). In addition to competition with BDBV43, EBOV237 competed 190 
partially with EBOV29 or EBOV102 on EBOV sGP. EBOV237 did not compete for binding with the 191 
previously isolated non-neutralizing mAb BDBV91, which is known to bind to the hydrophobic pocket 192 
at the EBOV sGP dimer interface (13). 193 
 194 
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 10 
To identify key residues recognized by EBOV237, mutations were introduced into GP through alanine 195 
scanning Shotgun Mutagenesis of EBOV GPΔmucin (Ebola virus H.sapiens-tc/COD/1976/Yambuku-196 
Mayinga (31), Δ311-461). Identification of the residues N278 and P279 as critical residues for binding 197 
confirmed that the EBOV237 epitope lies within the glycan cap region of GP1 (Figure 3C or 3D). The 198 
critical residues for EBOV237 are conserved in BDBV, supporting the cross-reactivity profile of 199 
EBOV237 to BDBV GP. However, the reduction in binding of EBOV237 to BDBV GP (EC50 value of 200 
3,367 ng/mL) suggests that other factors may be involved. This is also consistent with the cross-201 
reactivity profile of EBOV237, in SUDV (not recognized by EBOV237) residues 278 and 279 are 202 
D278 and A279, respectively. The glycan cap region of GP1 also is bound by the ZMapp cocktail mAb 203 
13C6. Residues G264 to W275, identified for binding of this mAb to EBOV GP, lie at the tip of the 204 
glycan cap (13,21). The difference in residues bound by EBOV237 and 13C6 is consistent with the 205 
differences observed in the competition-binding assays done with EBOV GP (Figure 3A). Thus, even 206 
though these two mAbs bind to the glycan cap of GP1, EBOV237 and 13C6 recognize distinct residues 207 
or epitopes in this domain. 208 
 209 
To identify key residues selectively pressured to mutate in the presence of EBOV237, we isolated 210 
EbolaΔVP30-GFP neutralization escape mutant viruses. Sequence analysis of EBOV GP for the 211 
mutant viruses identified the mutated residues I260R and S322G. These two mutations were identified 212 
in four different independently selected neutralization escape mutant viruses (Figure 3F). PRNT assays 213 
confirmed the ablation of neutralization for escape mutant 4 in the presence of different concentrations 214 
of EBOV237 (Figure 3F). Plaque titers for escape mutant 4 were similar to those of the control mAb 215 
VP35 for wildtype or mutant viruses. Thus, EBOV237 selectively pressures the virus to mutate at these 216 
key residues as it binds the glycan cap of GP1, leading to escape of the virus from the neutralization 217 
capabilities of EBOV237. The escape mutation at I260 is consistent with glycan cap location and 218 
EBOV237 epitope (critical residues N278 and P279). However, the escape mutation S322G 219 
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 11 
presumably exerts an allosteric effect, since it is not located within the glycan cap but instead within 220 
the mucin-like domain. The EBOV237 cross-reactivity with sGP, which lacks residue S322, is also 221 
inconsistent with inclusion of S322 as part of the epitope. 222 
 223 
In vivo studies revealed a correlate of protection. Mouse challenge studies were performed to 224 
determine the prophylactic efficacy of EBOV237. Initially, groups of 10 female BALB/c mice, aged 6 225 
to 8 weeks, were treated intraperitoneally (i.p.) 24 hours prior to virus inoculation (day -1) with a 226 
single dose of 100 µg of EBOV237. For the positive control group, mice were treated i.p. with 100 µg 227 
of mAb 13C6. For the negative control group, mice were treated i.p. with an irrelevant IgG antibody. 228 
On day 0, mice were inoculated i.p. with 100 PFU of mouse adapted Ebola Zaire (Mayinga) (ma-229 
ZEBOV). Mice were monitored daily for 28 days after virus inoculation. EBOV237 provided a similar 230 
level of protection against ma-ZEBOV infection as the positive control mAb 13C6 (Figure 4A). An 231 
irrelevant negative control IgG antibody, did not protect mice from the lethal infection. To observe 232 
clinical signs of disease, mice were monitored twice daily for 28 days after virus inoculation (Figure 233 
4B). Individual disease score parameters included normal (0), reduced grooming/ruffled fur (1), 234 
subdued, but normal when stimulated (2), lethargic: hunched posture; subdued even when stimulated 235 
(3), nasal discharge/bleeding/unresponsive, when stimulated/weak/paralysis (4). Animals treated with 236 
the irrelevant negative control IgG antibody exhibited several signs of disease. Animals treated with 237 
mAb 13C6 or EBOV237 also showed some signs of disease. However, there was a reduction in signs 238 
of clinical disease for both of these groups, with a slight improvement shown for EBOV237. Group 239 
body weights were taken daily for 28 days after virus inoculation (Figure 4C). Groups treated with 240 
EBOV237 or 13C6 showed little variation in average weight of mice over the 28 days. The group 241 
treated with irrelevant negative control IgG antibody showed variation in average weight, 242 
corresponding with survival of the mice (Figure 4A). These data confirm the prophylactic efficacy of 243 
EBOV237 against ma-ZEBOV infection. 244 
 o
n
 February 6, 2019 by guest
http://jvi.asm.org/
D
ow
nloaded from
 
 12 
 245 
A dose-response curve also was performed to determine the efficacy of protection for EBOV237 246 
against mouse-adapted Ebola Zaire (Mayinga) (ma-ZEBOV) infection. At 24 hours prior to virus 247 
inoculation, groups of 10 female BALB/c mice aged 6 to 8 weeks were treated i.p. with a single dose 248 
of 200, 100, 50, or 25 µg of EBOV237. The positive and negative controls groups were the same as 249 
described for the initial study. On day 0, mice were inoculated i.p. with 100 PFU of ma-ZEBOV. Mice 250 
were monitored daily for 21 days after virus inoculation. Survival depended on the dose of EBOV237 251 
administered, with a dose of 200 µg providing similar protection against ma-ZEBOV infection to the 252 
positive control mAb 13C6 administered at 100 µg (Figure 5A). Animals treated with EBOV237 253 
showed reduction of signs of disease in a dose-dependent manner. Similar improvement of disease was 254 
observed for mice treated with 200 µg of EBOV237, and the positive control mAb 13C6 (Figure 5B). 255 
Little variation in the average weight of mice over the course of 21 days was observed for animals 256 
treated with any dose of EBOV237 compared to animals treated with the irrelevant negative control 257 
antibody.  258 
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 13 
DISCUSSION 259 
 260 
In this study, we found that the overall human B cell response to Zaire ebolavirus (EBOV) infection 261 
early in convalescence is low in EBOV-specific B cell frequency and the antibodies encoded are 262 
generally of limited neutralizing potency Most of the previous work on the human B cell response to 263 
EBOV infection has focused on cells obtained long after infection. At later time points, we and others 264 
have observed high frequency of circulating B cells that include clones encoding broad and potent 265 
protective antibodies (3-8). Previous serological studies suggest that some human EBOV survivors do 266 
not possess high titer neutralizing antibody responses until later after recovery from infection. It was 267 
uncertain if this observation was due to just a delayed or low level of secretion of antibodies by plasma 268 
cells, or if the response was fundamentally deficient in frequency of virus-specific B cells secreting 269 
high-quality antibodies. Using B cell clones, here we show here that the early response is characterized 270 
by both low magnitude of B cell response and poor functional quality of the antibodies specified by 271 
those B cells. Variation in antibody response was observed amongst these donors, however, with 272 
EVD2 and EVD5 exhibiting a higher and broader response to diverse EBOV species. It is unclear why 273 
there are differences in B cell reactivity from these donors. It is possible that differences in the 274 
treatments administered potentially contributes to the specific immune response for each donor, as 275 
donors EVD2 and EVD5 both received ZMapp whereas EVD9 and EVD15 an siRNA product and a 276 
DNA polymerase inhibitor, respectively, in addition to convalescent serum (22). Additionally, severity 277 
of disease may also account for these differences. Further studies are necessary to address the influence 278 
on the induction of a patient’s B cells following a specific treatment regimen for EVD. 279 
 280 
In total, we isolated 25 mAbs from four U.S. donors who survived EVD. Blood samples were collected 281 
at one to three-months post-discharge to represent early convalescence time points. Out of these mAbs, 282 
only one possessed detectable neutralization activity, EBOV237, which was isolated from donor EVD5 283 
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three-months post-discharge. It was interesting that the early B cell response was dominated by clones 284 
that recognized the secreted form of EBOV glycoprotein (sGP). This finding may indicate that the 285 
initial B cell response to EBOV infection is driven principally by sGP, which might serve as a decoy to 286 
allow for virus evasion of the immune response. The low frequency of neutralization activity from the 287 
isolated mAb panel suggests that the B cell response is of low quality and quantity early during 288 
infection and further implicates the importance of aggressive treatment of disease early during 289 
infection and during early convalescence.  290 
 291 
Identification of the neutralizing epitope recognized by EBOV237 through several laboratory methods 292 
revealed that EBOV237 recognizes a unique site within the glycan cap of GP1. In particular, residues 293 
N278 and P279, I260 and S322 were identified through alanine scanning mutagenesis and 294 
neutralization escape mutant viruses, respectively. This epitope is in a location, near the top of the 295 
glycan cap, similar to that of chimerized mouse antibodies included in the ZMapp cocktail, mAb13C6, 296 
and the ZMab cocktail, 1H3, that also recognize the glycan cap of GP1. However, mAbs 1H3 and 297 
13C6 are weakly neutralizing and the differences in epitope recognition by EBOV237 suggest this new 298 
mAb binds to a slightly different antigenic determinant within the glycan cap of GP1 that enables it to 299 
have stronger neutralization activity against EBOV. In addition to in vitro virus neutralization activity, 300 
EBOV237 also exhibited prophylactic activity, similar in comparison to the ZMapp cocktail mAb 301 
13C6, in a dose-dependent manner against infection and disease caused by the mouse adapted Ebola 302 
Zaire (Mayinga) (ma-ZEBOV) strain. 303 
 304 
The results presented here suggest that the human B cell response to EVD early in recovery is 305 
characterized by targeting the EBOV GP glycan cap or sGP, with a paucity of broad or potent 306 
neutralizing B cell clones. However, the neutralizing epitope in the glycan cap recognized by 307 
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EBOV237 may play a role in the early human antibody response to EVD and should be considered in 308 
rational design strategies for new EBOV vaccine candidates. 309 
  310 
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MATERIALS AND METHODS 311 
 312 
Research subjects. The subjects, designated EVD2, EVD5, EVD9, and EVD15, were patients who 313 
survived Ebola virus disease (EVD) and received treatment at Emory University Hospital in 2014. The 314 
clinical course and immune activation profiles for these patients were previously described (22, 26). 315 
Peripheral blood from the donors was collected one month and three-months post-discharge from the 316 
hospital. The sample that yielded the mAb EBOV237 is designated as EVD5_3, indicating the donor 317 
sample identification (EVD5) and time point of peripheral blood collection (three-months post-318 
discharge). Multiple PCR tests were performed to detect the presence of virus, which were negative, 319 
indicating the absence of virus at these time points. The Institutional Review Boards (IRBs) at Emory 320 
University and Vanderbilt University Medical Center approved the protocol for the recruitment and 321 
collection of blood samples used in this study. Specifically, the subjects were enrolled under an Emory 322 
protocol, IRB00076700, The Longitudinal Characterization of Immune Responses to Ebola Virus 323 
Infections. The samples were obtained after the subjects gave written informed consent. PBMCs were 324 
isolated and cryopreserved in liquid nitrogen until use.  325 
 326 
Generation of human hybridomas. Previously cryopreserved PBMCs were thawed rapidly in a 37 ºC 327 
water bath. The cells were washed and resuspended in pre-warmed Medium A (ClonaCell
TM
-HY 328 
#03801) prior to Epstein-Barr virus (EBV) transformation. In 16 mL of B cell growth medium 329 
(Medium A, 50 L CpG (2.5 mg/mL; Invitrogen Oligonucleotide: ZOEZOEZZZZZOEEZOEZZZT), 330 
15 L Chk2 inhibitor (10 mM in DMSO; Sigma #C3742), and 20 L cyclosporin A (1 mg/mL in 331 
ethanol; Sigma #C1832)), 4.5 mL of filtrate containing EBV from the B95.8 cell line (ATCC CRL-332 
1612
TM
) was added. The PBMCs then were added and plated at 50 L/well for 8-10 million cells per 333 
384-well plate (Thermo Scientific #164688). After 7-10 days at 37 °C, cells were expanded into four 334 
 o
n
 February 6, 2019 by guest
http://jvi.asm.org/
D
ow
nloaded from
 
 17 
96-well plates (Falcon #353072) at 200 L/well in 20 mL of B cell expansion media (Medium A, 50 335 
L CpG, 15 L Chk2 inhibitor, and irradiated (9,000 rads) heterologous human PBMCs (Nashville 336 
Red Cross) at 10 million cells/mL) per 96-well plate. The plates were incubated for an additional 4 337 
days at 37 °C, prior to screening by ELISA with purified glycoproteins (described below and as 338 
previously described (3)). Cells from positive wells containing supernatant reactive for an EBOV-339 
specific ELISA were added to 1 mL of pre-warmed BTX cytofusion medium (300 mM sorbitol (Sigma 340 
#36021), 0.1 mM calcium acetate (Fisher #AC21105-2500), 0.5 mM magnesium acetate (Fisher 341 
#AC42387-0050), and 1 mg/mL bovine serum albumin (BSA) (Sigma #A9418)) in microcentrifuge 342 
tubes. The microcentrifuge tubes were centrifuged at 3,000 rpm for 4 minutes and the supernatant was 343 
decanted. This procedure was repeated for a total of three times. HMMA 2.5 cells were washed 3x in 344 
BTX cytofusion medium and resuspended in BTX cytofusion medium for a total of 10 million 345 
cells/mL. HMMA 2.5 nonsereting myeloma cells then were added to the microcentrifuge tubes 346 
containing the positive EBV-transformed B cell pellet, for a total of 1.15 million cells per fusion. 347 
These cells were resuspended and transferred to a cytofusion cuvette (BTX Catalog No. 450125). 348 
Electrofusion of the cells was performed as described previously (27). The cuvettes were incubated at 349 
37 °C for 30 minutes. The cells then were added to 21 mL of HAT medium (400 mL of Medium A, 350 
100 mL of Medium E (ClonaCell
TM
-HY #03805), 50x HAT medium supplement (100 M 351 
hypoxanthine, 0.4 M aminopterin, 16 M thymidine; Sigma #H0262), 150 L ouabain octahydrate (1 352 
mg/mL; Sigma #O3125)) and plated at 50 L/well in 384-well plates. The plates were incubated for a 353 
total of 18 days at 37 °C in 7% CO2, prior to screening by ELISA. 354 
 355 
Human mAb production and purification. Positive wells from hybridoma fusions containing 356 
supernatant reactive for an EBOV-specific ELISA were cloned biologically by single-cell 357 
fluorescence-activated cell sorting. These clones then were expanded serially in 1, 2, and then 30 mL 358 
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of Medium E into 48-well plates (Corning #3548), 12-well plates (Corning #3513), and T-75-cm
2 
359 
flasks (Corning #430641), respectively. For each T-75-cm
2
 flask, the cells were scraped and expanded 360 
further into four T-225-cm
2
 flasks (Corning #431082) in 250 mL of serum free medium (Hybridoma-361 
SFM Gibco #12045-076). After 21 days at 37 °C, the supernatants were filtered using a 0.2-m pore 362 
size filter. Antibodies were purified from the filtrate using HiTrap Protein G or HiTrap MabSelectSure 363 
columns (GE Healthcare Life Sciences #17040501 and #11003494, respectively). 364 
 365 
Screening ELISA. Soluble forms of the full-length extracellular domain of Ebola Zaire (EBOV), 366 
Ebola Bundibugyo (BDBV), Ebola Sudan (SUDV), Marburg virus (MARV) glycoproteins (GPs) (1 367 
g/mL) or EBOV secreted GP (sGP) (1 g/mL) were diluted in 1x D-PBS to coat 384-well ELISA 368 
plates (Thermo Scientific #265203) at 25 L/well and incubated at 4 °C overnight. The plates were 369 
washed 3x with D-PBS-T (1x DPBS + 0.05% Tween 20) and blocked for 1 hour at room temperature 370 
with blocking solution (1% non-fat dry milk (Blotting Grade Blocker Bio-Rad #170-6404), 1% goat 371 
serum (Gibco 16210-072) in D-PBS-T). After blocking, the plates then were washed 3x with D-PBS-T 372 
and 10 L/well of supernatant from wells containing EBV-transformed B cells was added. Plates were 373 
incubated for 2 hours at room temperature and then washed 3x with D-PBS-T. A solution of secondary 374 
antibodies (goat anti-human IgG Fc gamma fragment specific alkaline phosphatase conjugated; 375 
Meridian Life Science, W99008A) at a 1:4,000 dilution in blocking solution then was added at 25 376 
L/well for 1 hour at room temperature. Alkaline phosphatase substrate solution (phosphatase 377 
substrate tablets (Sigma #S0942) in AP substrate buffer (1M Tris aminomethane (Fisher #BP152-5), 378 
30 mM MgCl2 (Sigma #M1028)) was added at 25 L/well following plate washing 6x with 1x D-PBS-379 
T. Plates were incubated at room temperature in the dark for 2 hours then read at an optical density of 380 
405 nm with a Biotek plate reader. Reactive wells were chosen based of an optical density > 0.5 nm. 381 
For data visualization, the Circos software package was used (28). 382 
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 383 
Recombinant glycoprotein. For the production of recombinant EBOV, BDBV, SUDV, MARV GP 384 
ectodomains (amino acids 1-636) and EBOV sGP (amino acids 1-316), stable Drosophila S2 cell lines 385 
were generated. Briefly, Effectene transfection reagent (Qiagen) was used to transfect S2 cells with 386 
modified pMTpuro vector plasmids containing the GP gene of interest, followed by stable selection of 387 
transfected cells with 6 µg/mL puromycin in complete Schneider's medium. Stable cells were 388 
transitioned to Insect Xpress medium (Lonza) in shaker culture and GP ectodomain expression was 389 
induced with 0.5 mM CuSO4. Supernatants were harvested after 4 days. All proteins were engineered 390 
with a double strep tag at the C terminus to facilitate purification using Streptactin resin (Qiagen), and 391 
the GPs further purified by Superdex 200 size exclusion chromatography in TBS or PBS buffer.  392 
 393 
Viruses and cells. Neutralization assays were performed using a virus stock containing Ebola virus 394 
Zaire (EBOV/Kik-9510621, CDC#807224, Vero E6p2), which was passed additionally in Vero cell 395 
monolayer cultures once and Vero E6 cell monolayer cultures twice (Vero E6p2, Vero p1, E6p2). 396 
Mouse-adapted Ebola Zaire (ma-ZEBOV) was prepared from the original Bray stock (1976 strain, 397 
Mayinga) (29) with an additional passage on Vero E6 cell monolayer cultures (Mp3, Vp2, Mp9, 398 
ppGH, Vp1). For plaque reduction neutralization test (PRNT) assays, a biologically contained Ebola 399 
virus, EbolaΔVP30 virus, was generated as previously described possessing the green fluorescent 400 
protein (GFP) reporter gene, instead of the VP30 open reading frame in the viral genome (30). 401 
VeroVP30 cells were maintained in complete growth medium (10% fetal bovine serum [FBS], 1x 402 
MEM with antibiotics and supplements), and EbolaΔVP30-GFP virus was propagated in a reduced 403 
medium (2% FBS, 1x MEM with antibiotics and supplements) as previously described (30). 404 
EbolaΔVP30 viruses were approved for use under biosafety level-2 containment at the University of 405 
Wisconsin - Madison by the NIH and CDC in February 2016. 406 
 407 
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 20 
Half-maximal effective concentration (EC50) binding ELISA analysis. EBOV, BDBV, SUDV, 408 
MARV GP, or EBOV sGP (1 g/mL) were prepared in 1x DPBS to coat 384-well ELISA plates at 25 409 
L/well and incubated at 4 °C overnight. The plates were washed 3x with D-PBS-T and blocked for 1 410 
hour at room temperature with blocking solution (1% non-fat dry milk, 1% goat serum, D-PBS-T). 411 
After blocking, the plates were washed 3x with D-PBS-T and 25 L/well of 3-fold serially diluted 412 
purified EBOV human mAb (30 g/mL – 170 ng/mL) in blocking solution was added. A solution of 413 
secondary antibodies (goat anti-human IgG Fc gamma fragment specific alkaline phosphatase 414 
conjugated; Meridian Life Science, W99008A) at a 1:4,000 dilution in blocking solution was added at 415 
25 L/well for 1 hour at room temperature. Alkaline phosphatase substrate solution was added at 25 416 
L/well following plate washing 6x with D-PBS-T. Plates were incubated at room temperature in the 417 
dark for 2 hours then read at an optical density of 405 nm with a Biotek plate reader. EC50 values were 418 
calculated using a non-linear regression analysis of the curves generated in Prism v.5. (GraphPad 419 
Software). 420 
 421 
Neutralization assay. Virus-specific neutralizing antibody responses were titrated in a plaque 422 
reduction neutralization test (PRNT), as previously described (4). Antibodies were diluted serially in 423 
Minimal Essential Medium (Corning Cellgro, Manassas, VA) containing 5% heat-inactivated fetal 424 
bovine serum (Gibco-Invitrogen, Gaithersburg, MD), 1X Antibiotic-Antimycotic (Gibco-Invitrogen, 425 
Gaithersburg, MD) (MEM complete) and incubated 1 hour at 37
 
°C with virus. After incubation, the 426 
antibody-virus mixture was added in duplicate to 6-well plates containing 90-95% confluent 427 
monolayers of Vero E6 cells. Plates were incubated for 1 hour at 37 °C with gentle rocking every 15 428 
minutes. Following the incubation, wells were overlaid with 0.5% agarose in supplemented EBME 429 
medium, 10% heat-inactivated fetal bovine serum (Gibco-Invitrogen, Gaithersburg, MD), 2X 430 
Antibiotic-Antimycotic (Gibco-Invitrogen, Gaithersburg, MD), and plates were incubated at 37 °C in 431 
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5% CO2 for 7 days. On day 7, cells were stained by the addition of a second overlay prepared as above 432 
containing 4-5% neutral red. Plates were incubated for 18-24 hours at 37 °C in 5% CO2. The endpoint 433 
titer was determined to be the highest dilution with ≥50% or ≥80% reduction (PRNT50, PRNT80) in the 434 
number of plaques observed to virus only control wells. 435 
 436 
Plaque reduction neutralization test (PRNT). To determine the neutralizing activity of EBOV237, a 437 
standard PRNT was performed with EbolaΔVP30-GFP virus (30). Approximately 200 plaque-forming 438 
units (PFU) of virus was incubated with EBOV237 (serial ten-fold dilutions of antibody in reduced 439 
medium) or a VP35 mAb as a control for 60 minutes at 37 °C. After incubation, standard plaque assays 440 
were performed (in triplicate) in which the virus/antibody mix was inoculated on VeroVP30 cell 441 
monolayers for 60 minutes. After washing off unbound virus, cells were overlaid with 1.25% 442 
methycellulose medium and incubated for 7 days. Cells were fixed and an immunostaining assay using 443 
an antibody against VP40 was performed as previously described (30), and the number of plaques was 444 
counted in each well. 445 
 446 
Generation of antibody escape mutant viruses. To generate mutant viruses that no longer were 447 
neutralized, approximately 10,000 PFU of EbolaΔVP30-GFP virus were incubated with 5 μg/mL of 448 
EBOV237 at 37 °C for 60 minutes. After incubation, the virus/antibody mix was inoculated onto 449 
VeroVP30 cells, incubated for 60 minutes at 37 °C and after incubation, cells were washed three times 450 
with reduced medium. Any escape mutant viruses were propagated for 9 days in reduced medium 451 
containing 5 μg/mL of mAb EBOV237. Four individual escape mutant viruses were isolated by 452 
selection of resistant plaques (30), and virus stocks were generated for each escape mutant virus in 453 
reduced medium in the presence of EBOV237 (5 μg/mL). The sequence of the virus GP was 454 
determined using viral RNA isolated from the cell culture supernatant of the stock virus (RNeasy Mini 455 
Kit, Qiagen). An RT-PCR reaction (Verso 1-Step RT-PCR kit, Thermo Fisher Scientific) was 456 
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performed to amplify the viral GP gene using forward and reverse primers at position 6,000 and 8,110 457 
of the Zaire Ebola (strain Mayinga ’76) genome that flank the 5 and 3 open reading frame of the GP 458 
gene, respectively. The resulting RT-PCR product was blunt end cloned into the TOPO pCR-XL 459 
vector (Thermo Fisher Scientific) and the sequence of the GP was determined by Sanger DNA 460 
sequence method for plasmid DNA from 10 to 20 bacterial clones for each virus escape mutant. 461 
 462 
Competition-binding analysis using biolayer interferometry. For competition-binding experiments, 463 
EBOV GP or EBOV sGP were biotinylated using an EZ-link Micro NHS-PEG4-Biotinylation Kit 464 
(Thermo Scientific #21955). The biosensors were soaked for 10 minutes in 200 L of 1x kinetics 465 
buffer (ForteBio #18-1092), followed by a baseline signal measurement for 60 seconds. The 466 
biotinylated proteins (5 g/mL) then were immobilized onto streptavidin-coated biosensor tips 467 
(ForteBio #18-5019) for 120 seconds. After washing the biosensor tips by immersion into 1x kinetics 468 
buffer for 60 seconds, the biosensors were immersed into 1x kinetics buffer containing the first 469 
antibody (100 g/mL) for 600 seconds. The tips then were immersed into kinetics buffer containing the 470 
second antibody (100 g/mL) for 300 seconds. Comparison between the maximal signal of the second 471 
antibody in the absence or presence of the first antibody was used to determine the percent binding of 472 
the second antibody. If the percent binding of the second antibody was reduced to <30% of the 473 
maximal signal that occurred in the absence the first antibody, then the antibodies were considered to 474 
display full competition for binding. If the percent binding was reduced to 30 to 70% of the maximal 475 
signal that occurred in the absence of the first antibody, then the antibodies were considered to display 476 
intermediate competition for binding. If the percent binding was >70% of the maximal signal that 477 
occurred in the absence of the first antibody, then the antibodies were considered non-competing. 478 
 479 
 o
n
 February 6, 2019 by guest
http://jvi.asm.org/
D
ow
nloaded from
 
 23 
Fab production. To generate the Fab fragment of EBOV237, purified mAb IgG protein was digested 480 
with papain (Sigma #P3125; stock solution 0.1 mg/mL) at a ratio of 20:1 mAb:papain (wt:wt). 481 
Digestion was performed at 37 °C for 1h before termination by addition of 1/10 volume of 0.3 M 482 
iodoacetamide in PBS, followed by immediate 10-fold dilution in 10% NGS and storage at 4 °C. 483 
 484 
Alanine scanning Shotgun Mutagenesis for epitope mapping. We created an alanine scanning 485 
mutagenesis library for EBOV GP (21) using an expression construct of EBOV GPΔmucin (Ebola 486 
virus H.sapiens-tc/COD/1976/Yambuku-Mayinga (31), Δ311-461). Each of the amino acid residues 487 
33-310 and 462-676 of EBOV GPΔmucin were substituted in individual GP constructs one at a time to 488 
alanine (or alanine residues to serine). The signal peptide sequence, residues 1-32, was not altered. The 489 
alanine scanning mutagenesis library clones constituted 99.9% of the target residues (492 of 493) and 490 
the presence of the mutations was confirmed by DNA sequencing. Clones were arrayed at one mutant 491 
per well per into 384-well plates. HEK-293T cells were transfected with the mutant library. After 22 492 
hours incubation to allow for expression of the mutant GPs, the cells were either fixed with 4% 493 
paraformaldehyde in PBS with calcium and magnesium or unfixed. The cells then were incubated with 494 
the Fab fragment of EBOV237 in 10% normal goat serum (NGS) (Sigma-Aldrich, St. Louis, MO) for 495 
1 hour at room temperature. An Alexa Fluor 488-conjugated secondary antibody (Jackson 496 
ImmunoResearch Laboratories, Westgrove, PA) in 10% NGS was added, and the cells were incubated 497 
for 30 minutes at room temperature. The cells then were washed twice in PBS without calcium and 498 
magnesium and resuspended in Cellstripper (Cellgro, Manassas, VA) with 0.1% BSA (Sigma-Aldrich, 499 
St. Louis, MO). A multi-well automated flow cytometer (Intellicyt HTFS, Albuquerque, NM) then was 500 
used to detect cellular fluorescence. The relative EBOV237 Fab fragment reactivity to the mutants in 501 
comparison to the wild-type EBOV GPΔmucin was determined by subtracting the background signal 502 
given by mock vector transfected control cells and normalizing the signal to the wild-type EBOV 503 
GPΔmucin transfected control. Critical clones were determined if they did not bind the EBOV237 Fab 504 
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fragment but bound other control EBOV mAbs (EBOV296, EBOV442, EBOV520). This approach 505 
excludes mutants with misfolding or expression defects (32). The mutagenesis data was analyzed by 506 
detailed algorithms, as described previously (33). 507 
 508 
In vivo protection studies. All animal research was conducted under an IACUC-approved protocol in 509 
compliance with the Animal Welfare Act, PHS Policy, and other Federal statutes and regulations 510 
relating to animals and experiments involving animals. The facility where this research was conducted 511 
is accredited by the Association for Assessment and Accreditation of Laboratory Animal Care, 512 
International and adheres to principles stated in the Guide for the Care and Use of Laboratory Animals, 513 
National Research Council, 2011. Female BALB/c mice, aged 6 to 8 weeks, were purchased from 514 
Charles River Laboratory. Upon arrival, mice were housed in microisolator cages in an animal 515 
biosafety level 4 containment area and provided chow and water ad libitum. An initial study evaluated 516 
the efficacy of EBOV237 at a single concentration. Twenty-four hours before infection (day -1), 517 
groups of mice (10 mice per group) were treated intraperitoneally (i.p.) with a single dose (100 µg) of 518 
antibody. Negative control mice received an irrelevant, isotype-matched antibody. Positive control 519 
mice received 100 µg of the previously described mAb 13C6. On day 0, mice were inoculated by the 520 
i.p. route with 100 p.f.u. of ma-ZEBOV. Mice were monitored daily (twice daily if clinical signs of 521 
disease were noted) for 28 days after virus inoculation. Group weights were recorded daily after virus 522 
inoculation. Body weights were calculated by dividing group weight by number of mice weighed. In a 523 
second study, efficacy was evaluated at various decreasing doses. For this study, mice (n=10/group) 524 
were administered a single dose of 200, 100, 50 or 25 µg of EBOV237 at 24 hours before virus 525 
exposure. Negative control mice received an irrelevant isotype-matched antibody. Positive control 526 
mice received a single dose of 100 µg of mAb 13C6. On d0, mice were inoculated by the i.p. route 527 
with 100 p.f.u. of ma-ZEBOV. Mice were monitored daily (twice daily if there were clinical signs of 528 
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disease) for 21 days after virus inoculation. Group weights were recorded daily after virus inoculation. 529 
Body weights were calculated by dividing group weight by number of mice weighed.  530 
 o
n
 February 6, 2019 by guest
http://jvi.asm.org/
D
ow
nloaded from
 
 26 
ACKNOWLEDGEMENTS 531 
We thank the Emory Serious Communicable Diseases team for their efforts to collect samples from 532 
these patients, and the members of the Rafi Ahmed laboratory at Emory who separated and 533 
cryopreserved the survivor PBMCs. We thank Hannah King, Rebecca Lampley and Gopal Sapparapu 534 
for technical support with antibody protein preparation. This work was supported by U.S. NIH grants 535 
U19 AI109711 (to J.E.C.) and U19 AI109762 (to E.O.S.), Defense Threat Reduction Agency grant 536 
HDTRA1-13-1-0034 (to J.E.C.), HHS contract HHSN272201400058C (to J.E.C. and B.J.D.), Defense 537 
Advanced Research Project Agency grant W31P4Q-14-1-0010 (to J.E.C., Y.K.). The content is solely 538 
the responsibility of the authors and does not necessarily represent the official views of the NIH or the 539 
DOD. Flow cytometry experiments were performed in the VUMC Flow Cytometry Shared Resource, 540 
supported by NIH grants P30 CA68485 and DK058404.  541 
 542 
AUTHOR CONTRIBUTIONS 543 
L.E.W., A.I.F., P.J.G. Y.K., and J.E.C. planned the studies. L.E.W., A.I.F., N.K., R.B., S.R., E.D., 544 
M.L.F., E.O.S, P.J.H., A.E.P., and P.J.G. conducted experiments. A.B. generated the Circos plots. 545 
L.E.W., E.D., B.J.D., P.J.H, Y.K, P.J.G., and J.E.C. interpreted the studies. L.E.W. and J.E.C. wrote 546 
the first draft of the paper. E.O.S., B.J.D., Y.K., P.J.G., and J.E.C. obtained funding. 547 
DECLARATION OF INTERESTS 548 
S.R., E.D., and B.J.D. are employees of Integral Molecular. B.J.D. is a shareholder of Integral 549 
Molecular. J.E.C. is a consultant for Sanofi, is on the Scientific Advisory Boards of PaxVax, 550 
CompuVax, GigaGen, and Meissa Vaccines, is a recipient of previous unrelated research grants from 551 
Moderna and Sanofi and is founder of IDBiologics. All other authors declared no competing interests. 552 
  553 
 o
n
 February 6, 2019 by guest
http://jvi.asm.org/
D
ow
nloaded from
 
 27 
REFERENCES 554 
1. Travelers’ Health. Centers for Disease Control and Prevention. 2018. 555 
https://wwwnc.cdc.gov/travel/notices/watch/ebola-democratic-republic-of-the-congo (accessed 19 556 
August 2018) 557 
2. Ebola (Ebola Virus Disease). Centers for Disease Control and Prevention. 2017. 558 
https://www.cdc.gov/vhf/ebola/history/2014-2016-outbreak/index.html (accessed 19 August 2018) 559 
3. Flyak AI, Shen X, Murin CD, Turner HL, David JA, Fusco ML, Lampley R, Kose N, Ilinykh 560 
PA, Kuzmina N, Branchizio A, King H, Brown L, Bryan C, Davidson E, Doranz BJ, Slaughter 561 
JC, Sapparapu G, Klages C, Ksiazek TG, Saphire E, Ward AB, Bukreyev A, Jr JE. 2016. Cross-562 
Reactive and Potent Neutralizing Antibody Responses in Human Survivors of Natural Ebolavirus 563 
Infection. Cell 164:392–405. 564 
4. Bornholdt ZA, Turner HL, Murin CD, Li W, Sok D, Souders CA, Piper AE, Goff A, Shamblin 565 
JD, Wollen SE, Sprague TR, Fusco ML, Pommert KB, Cavacini LA, Smith HL, Klempner M, 566 
Reimann KA, Krauland E, Gerngross TU, Wittrup KD, Saphire EO, Burton DR, Glass PJ, 567 
Ward AB, Walker LM. 2016b. Isolation of potent neutralizing antibodies from a survivor of the 2014 568 
Ebola virus outbreak. Science 351:1078–83. 569 
5. Wec AZ, Herbert AS, Murin CD, Nyakatura EK, Abelson DM, Fels JM, He S, James RM, La 570 
Vega M-AA de, Zhu W, Bakken RR, Goodwin E, Turner HL, Jangra RK, Zeitlin L, Qiu X, Lai 571 
JR, Walker LM, Ward AB, Dye JM, Chandran K, Bornholdt ZA. 2017. Antibodies from a Human 572 
Survivor Define Sites of Vulnerability for Broad Protection against Ebolaviruses. Cell 169:878–573 
890.e15. 574 
6. Flyak AI, Kuzmina N, Murin CD, Bryan C, Davidson E, Gilchuk P, Gulka CP, Ilinykh PA, 575 
Shen X, Huang K, Ramanathan P, Turner H, Fusco ML, Lampley R, Kose N, King H, 576 
Sapparapu G, Doranz BJ, Ksiazek TG, Wright DW, Saphire EO, Ward AB, Bukreyev A, Crowe 577 
 o
n
 February 6, 2019 by guest
http://jvi.asm.org/
D
ow
nloaded from
 
 28 
JE. 2018. Broadly neutralizing antibodies from human survivors target a conserved site in the Ebola 578 
virus glycoprotein HR2-MPER region. Nat Microbiol 3:670–677. 579 
7. Saphire EO, Schendel SL, Fusco ML, Gangavarapu K, Gunn BM, Wec AZ, Halfmann PJ, 580 
Brannan JM, Herbert AS, Qiu X, Wagh K, He S, Giorgi EE, Theiler J, Pommert KBJB, Krause 581 
TB, Turner HL, Murin CD, Pallesen J, Davidson E, Ahmed R, Aman MJ, Bukreyev A, Burton 582 
DR, Crowe JE, Davis CW, Georgiou G, Krammer F, Kyratsous CA, Lai JR, Nykiforuk C, Pauly 583 
MH, Rijal P, Takada A, Townsend AR, Volchkov V, Walker LM, Wang C-II, Zeitlin L, Doranz 584 
BJ, Ward AB, Korber B, Kobinger GP, Andersen KG, Kawaoka Y, Alter G, Chandran K, Dye 585 
JM. 2018. Systematic Analysis of Monoclonal Antibodies against Ebola Virus GP Defines Features 586 
that Contribute to Protection. Cell 174:938–952.e13. 587 
8. Gilchuk P, Kuzmina N, Ilinykh PA, Huang K, Gunn BM, Bryan A, Davidson E, Doranz BJ, 588 
Turner HL, Fusco ML, Bramble MS, Hoff NA, Binshtein E, Kose N, Flyak AI, Flinko R, Orlandi 589 
C, Carnahan R, Parrish EH, Sevy AM, Bombardi RG, Singh PK, Mukadi P, Muyembe-Tamfum 590 
JJ, Ohi MD, Saphire EO, Lewis GK, Alter G, Ward AB, Rimoin AW, Bukreyev A, Crowe JE. 591 
2018. Multifunctional Pan-ebolavirus Antibody Recognizes a Site of Broad Vulnerability on the 592 
Ebolavirus Glycoprotein. Immunity. 593 
9. Qiu X, Wong G, Audet J, Bello A, Fernando L, Alimonti JB, Fausther-Bovendo H, Wei H, 594 
Aviles J, Hiatt E, Johnson A, Morton J, Swope K, Bohorov O, Bohorova N, Goodman C, Kim D, 595 
Pauly MH, Velasco J, Pettitt J, Olinger GG, Whaley K, Xu B, Strong JE, Zeitlin L, Kobinger 596 
GP. 2014. Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp. Nature 597 
514:47–53. 598 
10. Corti D, Misasi J, Mulangu S, Stanley DA, Kanekiyo M, Wollen S, Ploquin A, Doria-Rose 599 
NA, Staupe RP, Bailey M, Shi W, Choe M, Marcus H, Thompson EA, Cagigi A, Silacci C, 600 
Fernandez-Rodriguez B, Perez L, Sallusto F, Vanzetta F, Agatic G, Cameroni E, Kisalu N, 601 
Gordon I, Ledgerwood JE, Mascola JR, Graham BS, Muyembe-Tamfun J-JJ, Trefry JC, 602 
 o
n
 February 6, 2019 by guest
http://jvi.asm.org/
D
ow
nloaded from
 
 29 
Lanzavecchia A, Sullivan NJ. 2016. Protective monotherapy against lethal Ebola virus infection by a 603 
potently neutralizing antibody. Science 351:1339–42. 604 
11. Gilchuk P, Mire CE, Geisbert JB, Agans KN, Deer DJ, Cross RW, Slaughter JC, Flyak AI, 605 
Mani J, Pauly MH, Velasco J, Whaley KJ, Zeitlin L, Geisbert TW, Crowe JE. 2018. Efficacy of 606 
Human Monoclonal Antibody Monotherapy Against Bundibugyo Virus Infection in Nonhuman 607 
Primates. J. Infect. Dis. 608 
12. Ebola virus disease. World Health Organization. http://www.who.int/en/news-room/fact-609 
sheets/detail/ebola-virus-disease (accessed 19 August 2018) 610 
13. Pallesen J, Murin CD, Val N de, Cottrell CA, Hastie KM, Turner HL, Fusco ML, Flyak AI, 611 
Zeitlin L, Crowe JE, Andersen KG, Saphire EO, Ward AB. 2016. Structures of Ebola virus GP and 612 
sGP in complex with therapeutic antibodies. Nat Microbiol 1:16128 613 
14. Lee JE, Fusco ML, Hessell AJ, Oswald WB, Burton DR, Saphire EO. 2008. Structure of the 614 
Ebola virus glycoprotein bound to an antibody from a human survivor. Nature 454: 177-182. 615 
15. Bornholdt ZA, Ndungo E, Fusco ML, Bale S, Flyak AI, Crowe JE, Chandran K, Saphire EO. 616 
2016a. Host-Primed Ebola Virus GP Exposes a Hydrophobic NPC1 Receptor-Binding Pocket, 617 
Revealing a Target for Broadly Neutralizing Antibodies. MBio 7:e02154–15. 618 
16. Hashiguchi T, Fusco ML, Bornholdt ZA, Lee JE, Flyak AI, Matsuoka R, Kohda D, Yanagi Y, 619 
Hammel M, Crowe JE, Saphire EO. 2015. Structural basis for Marburg virus neutralization by a 620 
cross-reactive human antibody. Cell 160:904–912. 621 
17. Misasi J, Gilman MS, Kanekiyo M, Gui M, Cagigi A, Mulangu S, Corti D, Ledgerwood JE, 622 
Lanzavecchia A, Cunningham J, Muyembe-Tamfun JJ, Baxa U, Graham BS, Xiang Y, Sullivan 623 
NJ, McLellan JS. 2016. Structural and molecular basis for Ebola virus neutralization by protective 624 
human antibodies. Science 351:1343–6. 625 
18. Wec AZ, Nyakatura EK, Herbert AS, Howell KA, Holtsberg FW, Bakken RR, Mittler E, 626 
Christin JR, Shulenin S, Jangra RK, Bharrhan S, Kuehne AI, Bornholdt ZA, Flyak AI, Saphire 627 
 o
n
 February 6, 2019 by guest
http://jvi.asm.org/
D
ow
nloaded from
 
 30 
EO, Crowe JE, Aman MJ, Dye JM, Lai JR, Chandran K. 2016. A “Trojan horse” bispecific-628 
antibody strategy for broad protection against ebolaviruses. Science 354:350–354. 629 
19. Audet J, Wong G, Wang H, Lu G, Gao GF, Kobinger G, Qiu X. 2014. Molecular 630 
characterization of the monoclonal antibodies composing ZMAb: a protective cocktail against Ebola 631 
virus. Sci Rep 4:6881. 632 
20. Murin CD, Fusco ML, Bornholdt ZA, Qiu X, Olinger GG, Zeitlin L, Kobinger GP, Ward AB, 633 
Saphire EO. 2014. Structures of protective antibodies reveal sites of vulnerability on Ebola virus. 634 
Proc. Natl. Acad. Sci. U.S.A. 111:17182–7. 635 
21. Davidson E, Bryan C, Fong RH, Barnes T, Pfaff JM, Mabila M, Rucker JB, Doranz BJ. 2015. 636 
Mechanism of Binding to Ebola Virus Glycoprotein by the ZMapp, ZMAb, and MB-003 Cocktail 637 
Antibodies. J. Virol. 89:10982–92. 638 
22. McElroy AK, Akondy RS, Davis CW, Ellebedy AH, Mehta AK, Kraft CS, Lyon GM, Ribner 639 
BS, Varkey J, Sidney J, Sette A, Campbell S, Ströher U, Damon I, Nichol ST, Spiropoulou CF, 640 
Ahmed R. 2015. Human Ebola virus infection results in substantial immune activation. Proc. Natl. 641 
Acad. Sci. U.S.A. 112:4719–24. 642 
23. Shantha JG, Mattia JG, Goba A, Barnes KG, Ebrahim FK, Kraft CS, Hayek BR, Hartnett 643 
JN, Shaffer JG, Schieffelin JS, Sandi JD, Momoh M, Jalloh S, Grant DS, Dierberg K, Chang J, 644 
Mishra S, Chan AK, Fowler R, O’Dempsey T, Kaluma E, Hendricks T, Reiners R, Reiners M, 645 
Gess LA, ONeill K, Kamara S, Wurie A, Mansaray M, Acharya NR, Liu WJ, Bavari S, Palacios 646 
G, Teshome M, Crozier I, Farmer PE, Uyeki TM, Bausch DG, Garry RF, Vandy MJ, Yeh S. 647 
2018. Ebola Virus Persistence in Ocular Tissues and Fluids (EVICT) Study: Reverse Transcription-648 
Polymerase Chain Reaction and Cataract Surgery Outcomes of Ebola Survivors in Sierra Leone. 649 
EBioMedicine 30:217–224. 650 
 o
n
 February 6, 2019 by guest
http://jvi.asm.org/
D
ow
nloaded from
 
 31 
24. Varkey J, Shantha J, Crozier I, Kraft C, Lyon M, Mehta A, Kumar G, Smith J, Kainulainen 651 
M, Whitmer S, Ströher U, Uyeki T, Ribner B, Yeh S. 2015. Persistence of Ebola Virus in Ocular 652 
Fluid during Convalescence. New Engl J Medicine 372:2423–2427. 653 
25. Fischer WA, Brown J, Wohl DA, Loftis AJ, Tozay S, Reeves E, Pewu K, Gorvego G, Quellie 654 
S, Cunningham CK, Merenbloom C, Napravnik S, Dube K, Adjasoo D, Jones E, Bonarwolo K, 655 
Hoover D. 2017. Ebola Virus Ribonucleic Acid Detection in Semen More Than Two Years After 656 
Resolution of Acute Ebola Virus Infection. Open Forum Infect Dis 4:ofx155. 657 
26. Lyon MG, Mehta AK, Varkey JB, Brantly K, Plyler L, McElroy AK, Kraft CS, Towner JS, 658 
Spiropoulou C, Ströher U, Uyeki TM, Ribner BS. Clinical Care of Two Patients with Ebola Virus 659 
Disease in the United States. New England Journal of Medicine 371:2402–2409. 660 
27. Yu X, McGraw PA, House FS, Crowe JE. 2008. An optimized electrofusion-based protocol for 661 
generating virus-specific human monoclonal antibodies. J. Immunol. Methods 336:142–51. 662 
28. Krzywinski M, Schein J, Birol I, Connors J, Gascoyne R, Horsman D, Jones SJ, Marra MA. 663 
2009. Circos: an information aesthetic for comparative genomics. Genome Res. 19:1639–45. 664 
29. Bray M, Davis K, Geisbert T, Schmaljohn C, Huggins J. 1999. A mouse model for evaluation 665 
of prophylaxis and therapy of Ebola hemorrhagic fever. J. Infect. Dis. 179 Suppl 1:S248–58. 666 
30. Halfmann P, Kim JH, Ebihara H, Noda T, Neumann G, Feldmann H, Kawaoka Y. 2008. 667 
Generation of biologically contained Ebola viruses. Proc. Natl. Acad. Sci. U.S.A. 105:1129–33. 668 
31. Kuhn JH, Andersen KG, Bào Y, Bavari S, Becker S, Bennett RS, Bergman NH, Blinkova O, 669 
Bradfute S, Brister JR, Bukreyev A, Chandran K, Chepurnov AA, Davey RA, Dietzgen RG, 670 
Doggett NA, Dolnik O, Dye JM, Enterlein S, Fenimore PW, Formenty P, Freiberg AN, Garry 671 
RF, Garza NL, Gire SK, Gonzalez J-PP, Griffiths A, Happi CT, Hensley LE, Herbert AS, Hevey 672 
MC, Hoenen T, Honko AN, Ignatyev GM, Jahrling PB, Johnson JC, Johnson KM, Kindrachuk 673 
J, Klenk H-DD, Kobinger G, Kochel TJ, Lackemeyer MG, Lackner DF, Leroy EM, Lever MS, 674 
Mühlberger E, Netesov SV, Olinger GG, Omilabu SA, Palacios G, Panchal RG, Park DJ, 675 
 o
n
 February 6, 2019 by guest
http://jvi.asm.org/
D
ow
nloaded from
 
 32 
Patterson JL, Paweska JT, Peters CJ, Pettitt J, Pitt L, Radoshitzky SR, Ryabchikova EI, Saphire 676 
EO, Sabeti PC, Sealfon R, Shestopalov AM, Smither SJ, Sullivan NJ, Swanepoel R, Takada A, 677 
Towner JS, Groen G van der, Volchkov VE, Volchkova VA, Wahl-Jensen V, Warren TK, 678 
Warfield KL, Weidmann M, Nichol ST. 2014. Filovirus RefSeq entries: evaluation and selection of 679 
filovirus type variants, type sequences, and names. Viruses 6:3663–82. 680 
32. Paes C, Ingalls J, Kampani K, Sulli C, Kakkar E, Murray M, Kotelnikov V, Greene TA, 681 
Rucker JB, Doranz BJ. 2009. Atomic-level mapping of antibody epitopes on a GPCR. J. Am. Chem. 682 
Soc. 131:6952–4. 683 
33. Davidson E, Doranz BJ. 2014. A high-throughput shotgun mutagenesis approach to mapping B-684 
cell antibody epitopes. Immunology 143:13–20. 685 
34. Zhao Y, Ren J, Harlos K, Jones DM, Zeltina A, Bowden TA, Padilla-Parra S, Fry EE, Stuart 686 
DI. 2016. Toremifene interacts with and destabilizes the Ebola virus glycoprotein. Nature 535:169–687 
172.  688 
 o
n
 February 6, 2019 by guest
http://jvi.asm.org/
D
ow
nloaded from
 
 33 
FIGURE LEGENDS 689 
 690 
Figure 1. Circos plot representation of the four EVD survivors’ cross-reactive B cell responses. 691 
(A and B) PBMC samples isolated from donors EVD2, EVD5, EVD9, and EVD15 one-month (A) or 692 
three-months (B) post-discharge were transformed with EBV and subsequently expanded. The 693 
supernatants from the transformed B cell lines were screened initially for binding to the soluble form 694 
of full-length extracellular domain of MARV, SUDV, EBOV, or BDBV GP. The height of the lines 695 
indicates the relative intensity of the optical density (OD) values at 405 nm as determined by ELISA 696 
using the indicated GP. Black lines indicated the antibody bound only to GP from one species. Orange, 697 
blue, and red lines represent cross-reactive B cell responses to GP from two, three, or four virus 698 
species, respectively. For PBMC samples isolated from donors EVD9 and EVD15 at three-months 699 
post-discharge, supernatant reactivity from transformed B cell lines was not tested against MARV GP. 700 
(C) The reactivity of EBOV, BDBV, SUDV GP and EBOV B cell lines are represented as the 701 
percentage of total GP and/or sGP-specific B cell lines. Positive reactivity was determined by >0.8 702 
optical density values at 405 nm. The values are heat mapped according to percent reactivity with 703 
>60% in dark green, 30-60% in lighter green, and <30% in light green. 704 
 705 
Figure 2. Binding and neutralization characterization of mAb EBOV237. (A) Twenty-five human 706 
monoclonal antibodies (mAbs) were isolated from the four EVD survivors, with respective subject 707 
number and month of PBMC isolation post-discharge indicated. These mAbs are organized into groups 708 
and subgroups based on their breadth of binding for diverse GPs. Of the 25 mAbs, all but three bound 709 
to EBOV GP. Two of these mAbs bound only to full-length EBOV sGP and are referred to as “sGP”. 710 
Subgroup A includes mAbs able to bind to full-length EBOV GP and EBOV sGP. Subgroup B 711 
includes the mAbs that bound only to full-length EBOV GP. Group 1, 2, and 3 indicate the breadth of 712 
the mAb to EBOV, EBOV and BDBV, and EBOV, BDBV, and SUDV GP, respectively. The EC50 713 
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values (ng/mL) <100 ng/mL are in red, < 1,000 ng/mL in orange, and < 10,000 ng/mL in yellow. EC50 714 
values (ng/mL) > 10,000 ng/mL are in white and indicated with the symbol >. The EC50 values shown 715 
are an average of technical triplicates, and are representative of two duplicate ELISAs, with similar 716 
results. Neutralization data for each mAb is shown as either positive or negative, with EBOV237 717 
shown in red. (B) Binding curve for EBOV237 to full-length EBOV, BDBV, SUDV, MARV GP or 718 
EBOV sGP, as measured by OD at 405 nm with increasing mAb concentration. (C) Neutralization data 719 
of EBOV237 as determined by plaque reduction neutralization tests (PRNT) at 50% (PRNT50) or 80% 720 
(PRNT80) reduction, corresponding with the indicated IC50 values of 0.75 µg/mL and 1.56 µg/mL, 721 
respectively. 722 
 723 
Figure 3. Epitope mapping of EBOV237 as determined by competition-binding and shotgun 724 
mutagenesis indicates binding to the glycan cap. (A and B) Competition-binding analysis of mAbs 725 
to full-length EBOV GP (A) and EBOV sGP (B) are indicated. The numbers indicate residual percent 726 
binding of the second antibody in the presence of the first antibody, in comparison to the absence of 727 
the first antibody. A reduction in percent binding of the second antibody to <30% due to the presence 728 
of the first antibody (black boxes with white numbers), indicates full competition for binding. A 729 
reduction in percent binding of the second antibody to 30 to 70% due to the presence of the first 730 
antibody (grey boxes with black numbers), indicates intermediate competition. A reduction in percent 731 
binding of the second antibody <30% due to the presence of the first antibody (white boxes with red 732 
numbers), indicates a lack of competition. (C, D, E) EBOV237 was epitope mapped by screening on 733 
an EBOV Δmucin GP alanine scan mutation library expressed in HEK-293T cells, with binding by 734 
EBOV237 assayed by flow cytometry. This identified N278A and P279A as a critical clones that 735 
showed specifically reduced binding for EBOV237 Fab (<20% and <30% of binding to WT EBOV 736 
GP, respectively; red bar), but a high level of binding to control mAbs EBOV296, EBOV442, or 737 
EBOV520 (gray/white bars) (C). Error bars represent the mean and range (half of the maximum minus 738 
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minimum values) of at least two replicate data points. The monomer (D; side view) or trimer (E; top 739 
view) form of EBOV ∆mucin GP, with GP1 in yellow and GP2 in red (PDB: 5JQ3) is shown (34). The 740 
critical binding residues for EBOV237 (N278, P279, and I260) to EBOV ∆mucin GP are indicated by 741 
the green spheres on either structure. S322 is not shown as this residue corresponds to the mucin-like 742 
domain of EBOV GP. (F) Four antibody neutralization escape mutant viruses were isolated, each with 743 
the mutations I260R and S322G. A plaque reduction neutralization test (PRNT) assay was done using 744 
10, 1, 0.1, 0.01, or 0.001 µg of EBOV237 incubated with either wild-type (WT) virus or escape mutant 745 
4. The numbers for the assays, performed in triplicate, indicate plaque-forming units per well. 746 
 747 
Figure 4. EBOV237 provided prophylactic protection from mouse-adapted Ebola Zaire 748 
(Mayinga) infection. BALB/c mice in groups of 10 were each given 100 µg of EBOV237 749 
intraperiotenally 24 hours prior to challenge with 100 PFU of Mayinga virus intraperiotenally. (A) 750 
Kaplan-Meier survival curve indicates that EBOV237 provides similar protection against lethal disease 751 
as mAb 13C6, in comparison to the irrelevant negative control IgG. (B) Disease scores were recorded 752 
based on the sickest animal in each treatment group over the course of 28 days (normal (0), reduced 753 
grooming/ruffled fur (1), subdued, but normal when stimulated (2), lethargic: hunched posture; 754 
subdued even when stimulated (3), nasal discharge/bleeding/unresponsive, when 755 
stimulated/weak/paralysis (4)). Animals treated with mAb 13C6 or the irrelevant negative control IgG 756 
exhibited several signs of disease, with an improvement shown for EBOV237. (C) Average weight of 757 
mice (calculated from group weight dived by number of mice weighed) taken over a course of 28 days. 758 
Mice treated with EBOV237 or 13C6 showed little variation in average weight of mice over the course 759 
of study. Mice treated with the irrelevant negative control IgG antibody showed variation in average 760 
weight. 761 
 762 
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Figure 5. EBOV237 provides dose-dependent efficacy. Groups of ten mice were given either 200 763 
g, 100, 50, or 25 g EBOV-237, or 100 µg of a positive control mAb 13C6, or 100 µg of an 764 
irrelevant negative control IgG intraperioneally 24 hours prior to challenge with 100 PFU of Mayinga 765 
virus intraperiotenally. (A) Kaplan-Meier survival curve over the course of 21 days demonstrates the 766 
extent of survival depended on the dose of mAb. EBOV237 given at 200 µg provided a similar level of 767 
protection against lethal disease caused by Mayinga virus as mAb 13C6, in comparison to the 768 
irrelevant negative control IgG. (B) Individual disease scores were determined over the course of 21 769 
(normal (0), reduced grooming/ruffled fur (1), subdued, but normal when stimulated (2), lethargic: 770 
hunched posture; subdued even when stimulated (3), nasal discharge/bleeding/unresponsive, when 771 
stimulated/weak/paralysis (4)). Reduction of disease score was observed in a dose-dependent manner 772 
for animals treated with EBOV237. (C) Average weight of mice (calculated from group weight 773 
divided by number of mice weighed) taken over a course of 21 days. Mice treated with any dose of 774 
EBOV237 or 13C6 showed little variation in average weight of mice over the course of the study 775 
compared to mice treated with the irrelevant negative control IgG. 776 
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